Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of [14C]-TAK-954 in Healthy Men
NCT03500224Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of felcisetrag in enteral feeding intolerance (EFI), Postoperative gastrointestinal dysfunction (POGD) and gastroparesis, sponsored by Millennium Pharmaceuticals. Primary endpoints: Cumulative Percentage of Administered Radioactivity Recovered in Urine, Cumulative Percentage of Administered Radioactivity Recovered in Feces and 4 more. Started Apr 2018; status: completed.
02
Drugs
felcisetrag
03
Conditions
enteral feeding intolerance (EFI)Postoperative gastrointestinal dysfunction (POGD)gastroparesis
Beyond the preview
Go deeper on NCT03500224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03500224.